Welcome, Guest. Please login or register.
February 21, 2024, 10:26:09 am

Login with username, password and session length

  • Total Members: 6307
  • Latest: golfer
  • Total Posts: 55120
  • Total Topics: 4850
  • Online Today: 144
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 70
Total: 70


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: New Hepatitis C Drug *Daklinza* Gets European O.K.  (Read 6135 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
New Hepatitis C Drug *Daklinza* Gets European O.K.
« on: August 28, 2014, 01:06:41 pm »
FYI: The European Commission has just approved Bristol-Myers Squibb’s Daklinza (daclatasvir) to be used in combination with other medications, such as Sovaldi, to treat genotypes 1-4 of hepatitis C virus.

Scientists said in a recent press release: “We have a new class of drug that disrupts the virus in two ways—by inhibiting both viral replication and assembly—and when combined with other compounds often results in a cure among even the hardest-to-treat patients.”

An application for the drug is currently pending in the U.S. and Japan. Keep a lookout this November, when the FDA is set to review it!

For more info: http://www.hepmag.com/articles/Daklinza_EU_approval_2501_26078.shtml


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.